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Abstract
Introduction Sleep related breathing disorders (SRBD) cause sleep fragmentation, intermittent hypoxia or a combination of both
leading to homeostasis perturbations, including in the immune system. We investigated whether SRBD patients with or without
intermittent hypoxia show substantial differences in perforin and granzyme-B positive peripheral blood lymphocytes.
Methods A total of 87 subjects were included and distributed as follows: 24 controls (C), 19 patients with respiratory effort
related arousals due to increased upper airway resistance (UAR) without hypoxic events, 24 obese patients with obstructive sleep
apnea (OSA) (oOSA), and 20 without obesity (noOSA). After polysomnographic recording, we analyzed in fasting blood
samples routine hematologic and biochemical parameters and the percentage of lymphocytes containing the proteins perforin
and granzyme-B (GrB). Kruskal-Wallis tests and a posteriori multiple comparisons were applied for statistical analysis of results.
Results Perforin-positive γδ-cells revealed significant differences between groups (p = 0.017), especially between the Control
group and the oOSA (p-value = 0.04); the remaining SRBD groups also showed differences from the control (C vs UAR: p =
0.08; C vs noOSA = 0.09), but they did not raise to statistical significance. There were no differences among the SRBD groups.
Granzyme-B cells were decreased in SRBD patients, but the differences were not statistically significant. No additional statistical
significant result was found in the other investigated lymphocyte subsets.
Conclusions Obstructive sleep-disordered breathing is associated with a decrease in perforin-positive CD3+γδ-T cells. Although
this finding was detected in lean patients without intermittent hypoxia, the reduction was only statistically significant in obese
patients with severe OSA. Because CD3+γδ-T cells play an
important role in the control of tumor cells, our findings are
directly relevant for the study of the association of OSA and
cancer.
Keywords Sleep-related breathing disorders . Obstructive
sleep apnea . Perforin and granzyme-B-positive peripheral
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Introduction
Sleep is a critical adaptive behavior as it is essential for the
maintenance of core homeostatic functions of an organism. A
large body of evidence demonstrates the importance of sleep
not only for various metabolic and inflammatory pathways,
but also for humoral and cellular immune functions [1]. Sleep-
related breathing disorders (SRBD) in general and the obstruc-
tive sleep apnea (OSA) in particular are extremely prevalent in
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the general population, and therefore constitute a public health
problem. OSA is linked to increased mortality mainly due to
higher prevalence of cardiovascular events [2]. The underly-
ing mechanism is still under investigation but it is likely mul-
tifactorial. In addition to promoting a pro-atherogenic pattern
in the peripheral blood [3], OSA increases nuclear factor kap-
pa B (NFκB)-dependent endothelial inflammation [4]. Recent
research has linked cytotoxic lymphocytes (CTL) to
ateriosclerotic plaque instability and thus the risk of acute
cardio-vascular events [5]. The main mechanism of cellular
cytotoxicity is based on the secretion of the proteins perforin
and granzymes into immunological synapse between a cyto-
toxic lymphocyte and a target cell [6]. Ultimately, the combi-
nation of perforin and GrB induces cell death by activating the
caspase cascade leading to nuclear fragmentation and apopto-
sis [7]. While enhanced activity of cytotoxic lymphocytes
constitutes an attractive idea to explain the increased cardio-
vascular risk in OSA, currently, there is little evidence to sup-
port a causal link between OSA in humans and an increased
number or activity of perforin positive CD8+ lymphocytes [8].
Chronic inflammation is known to raise the risk of carcino-
genesis [9]. Interestingly, OSA has also been linked to carci-
nogenesis, opening new possibilities to account for the in-
creased mortality in OSA patients [10]. Intermittent hypoxia,
sleep fragmentation, and increase in adipose tissue are three
typical features of OSA patients. Any of them is known to
influence inflammatory cascades and the immune system
[11]. In this study, we tested the impact of each component
of OSA in the immune response by analyzing perforin and
GrB positive lymphocytes in non-obese patients with either
intermittent hypoxia (OSA) or non-hypoxic sleep
fragmentation.
Material and methods
Subjects
A total of 87 participants with an age between 20 and 59 years
were included in this study. A total of 24 controls (C) were
recruited from patients admitted to the sleep laboratory with-
out detected sleep disorders, healthy members of the hospital
employees or their relatives. All showed in the sleep study a
respiratory disturbance index (RDI) and an oxygen
desaturation index (ODI) < 5/h. Upper airway resistance
(UAR) was defined as sleep fragmentation by mainly respira-
tory effort related arousals (RERAs). Patients of this group
demonstrated a RDI > 5 and an ODI and apnea/hypopnea in-
dex (AHI) < 5/h. A total of 19 participants fulfilled the UAR
criteria. Patients with obstructive sleep apneas (OSA) were
defined by an apnea/hypopnea index (AHI) and ODI > 5/h.
A total of 20 lean OSA patients with a body mass index
(BMI) < 30 kg/m2 were detected (non-obese OSA or
noOSA). As positive control group 24 obese OSA (oOSA)
patients were included. Patients were not instructed to remain
on a special diet before the sleep study. Eight oOSA patients
were on regular cholesterol or diabetes mellitus therapy.
Patients on immune system modulating therapies (e.g., recent
vaccines or systemic corticoids) were excluded from this
study. This project was approved by the Ethics Committee
Review Board of Hospital de Santa Maria (Lisboa,
Portugal), and all participants signed informed consent forms.
Polysomnographic recordings
Sleep related events were investigated via standard
polysomnography (PSG) Alice 5, Koninklijke Philips N.V.
Philips Respironics, Murrysville, USA. The following parame-
ters were recorded: F3; F4; C3; C4; O1; O2, M1, and M2. We
used the standard referential montage of scalp electrodes against
the contra-lateral mastoid electrode (e.g., C3/M2). Further pa-
rameters consisted of submental electrodes, strain gauges to re-
cord respiratory movements, EMG at both legs according to
standard PSG procedures. Peripheral oxygen saturation was an-
alyzed by pulse oximetry. The scoring of sleep and sleep-related
events was based on the recommendation of the American
Academy of Sleep Medicine published in 2007 [12].
Evaluation of sleepiness
Sleepiness was evaluated using the Stanford Sleepiness Scale
(SSS) and the Epworth Sleepiness Scale (ESS). All patients
completed the questionnaires in the morning following the
polysomnographic recording.
Positive pressure therapy in OSA patients
All patients with a relevant OSA or UAR were invited to
receive continuous positive airway (CPAP) therapy. A total
of 42 patients (only with OSA) underwent another full poly-
somnographic recording with a CPAP titration protocol based
on the existing recommendations [13].
Blood analysis
Immediately after the diagnostic and therapeutic polysomno-
graphic study fasting peripheral blood samples were obtained
from a cubital vein and further analyzed in the laboratory.
Routine analysis
The following hematologic and biochemical parameters were
investigated in all participants following the diagnostic PSG
night: full peripheral blood cell count, hepatic enzymes (as-
partate transaminase (AST), alanine transaminase (ALT) and
gamma-glutamyltransferase (gGT)), renal parameters
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(creatinine, blood urea nitrogen (BUN)), standard metabolic
parameters (uric acid, glucose, total cholesterol, low density
lipoprotein (LDL), high density lipoprotein (HDL), triglycer-
ides (TG), and C-reactive protein (CRP)).
Analysis of the cytotoxic proteins perforin (P) and granzyme-B
(GrB)
P e r i p h e r a l v e n o u s b l o o d s amp l e a n d F i c o l l
Ethylenediaminetetraacetic acid (EDTA) anti-coagulated
blood was collected directly after the end of the sleep study
by peripheral venipuncture. Erythrocytes were lysed by
adding 10 ml of FACS lysis buffer (BD Biosciences,
Heidelberg, Germany). Peripheral blood mononuclear cells
(PMNCs) were isolated by standard Ficoll gradient separation
(FICOLL-PAQUE PLUS, GE Healthcare Biosciences).
Monoclonal antibodies Anti-human CD3-phycoerythrine
(PE) (clone UCHT1), CD4-PE (clone RPA-T4), CD8-PE
(clone HIT8), CD16 indotricarbocyanine dye coupled to PE
(PE-CY) (clone 4G8), CD56- PE-CY (cloneB159), perforin-
fluorescein isothiocyanate (FITC) (clone γG9) and granzyme-
B-FITC (clone GB11) were purchased from BD Biosciences,
Heidelberg, Germany. Additionally, we used the CD3-PE-CY-
(clone HIT3), and TCT-γδ-PE (clone B1) antibodies
manufactured by BioLegend, San Diego, USA.
Cell surface and intracellular staining Peripheral mononuclear
cells (pMNCs) were diluted to a concentration of 25 × 103
cells/well and supplemented with phosphate-buffered saline
(PBS) and 2% fetal calf serum (PBS/FCS buffer). After twice
washing with PBS/FCS buffer and centrifuged at 2000 rpm,
cells were incubated with 50 μg of a fluorochrome-labeled
anti-human antibody solution followed by washing with the
PBS/FCS solution. PMNCs were fixed with 2% paraformal-
dehyde in PBS for 30 min. After washing with PBS/FCS
buffer cells centrifugation at 200 rpm, cells were perme-
abilized with 150 ml saponin 0.1% in PBS buffer for
10 min. Following washing and centrifugation with
2000 rpm / 3 min, antibodies against intracellular and cyto-
toxic proteins were added in a 25 μl/well saponin 0.1% solu-
tion. Cells were washed with the 0.1% saponin solution
followed by two washed steps with PBS/FCS puffer.
Membrane and intracellular antigen expression on pMNCs
were in the following analyzed by flow cytometry (BD
Biosciences, Heidelberg, Germany). Using double surface
staining with PE or PE-Cy5labeled membrane antigens we
were able to investigate the following lymphocyte subsets:
CD3+CD4+, CD3+CD8+, CD3−CD8+, CD3+-γδ TCR+ (γδ-
T cells), CD3+CD16+/CD56+ (natural killer T cells (NKT))
and CD3−CD16+/CD56+ (NK cells). FITC labeling permitted
the additional analysis of the intracellular cytotoxic proteins
perforin and granzyme-B (Fig. 1).
Isolation of human peripheral blood γδ T cells
Blood from Buffy Coat units (50–70 mL) were obtained from
healthy volunteers. Blood was centrifuged in Ficoll-Paque
(Histopaque-1077; Sigma-Aldrich) for 35 min at 1.500 rpm
and room temperature. The interphase containing peripheral
blood mononuclear cells (PBMCs) was collected and washed
in PBS. The desired TCR γδ+ T lymphocytes were labeled by
incubation with hapten-conjugated anti-TCRγδ monoclonal
antibody (Miltenyi Biotec GmbH), according to the manufac-
turer’s instructions. Further, cells were labeled with FITC-
conjugated anti-hapten monoclonal antibody coupled to mag-
netic microbeads. The cell suspension was loaded onto a LS
magnetic column (Miltenyi Biotec) and TCRγδ+ T lympho-
cytes were positively selected. γδ+ T lymphocytes were sub-
sequently collected from the columns, following the manufac-
turer’s instructions, and resuspended in serum-free culture me-
dium (OpTmizer-CTS) supplemented with 5% fetal bovine
serum and 2 mM L-glutamine (Thermo Fisher Scientific)
and 70 ng/mL of interleukin-2.
Hypoxia induction in human peripheral blood γδ T
cells
Isolated human γδ T cells were plated in 96-well plates and
incubated at 37 °C, 5% CO2 and 19% O2 (normal condition),
in Heracell™ 150i CO2 Incubator (Thermo Fischer), or incu-
bated at 37 °C, 5% CO2 and 5% O2 (hypoxic condition), in
New Brunswick Scientific - Galaxy 14S CO2 Incubator (Wolf
Laboratories), for 24 h prior to cytokine production analysis
and cell surface staining by FACS.
Flow cytometry analysis
Cells were stained with the following antibodies from
Biolegend: anti-human CD107a (H4A3), anti-human
Granzyme B (GB11), and anti-human Perforin (#353312).
Antibodies were coupled with APC and Pacific Blue fluoro-
chromes. For intracellular cytokine production analysis, cells
were either stimulated with PMA+ Ionomycin + Brefeldin A
for 4 h at 37 °C or incubated only with Brefeldin A and further
stained with ebioscience IC kit according to the manufac-
turer’s instructions. Flow cytometry acquisition was per-
formed on a LSR Fortessa (BD) and data was analyzed with
FlowJo X software (Tree Star).
Statistics
Descriptive statistics and hypothesis testing were performed
using the Statistical Package for Social Science (SPSS) ver-
sion 21 (SPSS Inc., Chicago, IL, USA) software, and multiple
regression analysis was performed using R, version 3.4.1. (R
Development Core Team, 2008).
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Anthropometric data results are shown as mean (± SD).
Sleep and laboratory results were not normal distributed and
are shown as median (interquartile range). When two depen-
dent samples were analyzed, the Wilcoxon signed rank test
was applied. To compare between three or more different
groups Kruskal-Wallis tests were applied and a posteriori
Wilcoxon rank test for pairwise comparisons was performed,
using a Holm-Bonferroni adjustment for the obtained p-
values, due to the increasing probability of false positives
inherent to multiple comparisons. A significance level of al-
pha 5% was used to determine statistical significance.
Results
To investigate the effect of sleep disorders on cytotoxic im-
mune system, we divided the study population into four
groups, according to the diagnosis: in 24 of the total 87 in-
cluded participants we found no sleep related breathing disor-
ders (controls = C). In 19 patients, we detected sleep fragmen-
tation due to increased upper airway resistance (UAR) but an
apnea/hypopnea index within the normal range (< 5/H). A
total of 20 non-obese and 25 obese patients (noOSA and
oOSA, respectively) demonstrated an elevated obstructive
sleep apnea/hypopnea (AHI) index (≥ 5/h). The latter three
groups were considered to have sleep-related breathing disor-
ders (SRBD).
Anthropometric data
The anthropometric data is presented in Table 1. BMI was
higher in the oOSA group (p < 0.001) when compared to the
three other groups. Both OSA groups were older compared to
controls (p = 0.006 for noOSA, p = 0.007 for oOSA. There
were no evidences of any age differences between UAR group
and the controls.
Sleepiness evaluation and polysomnographic results
The results of the sleepiness questionnaires and the polysom-
nographic recordings can be seen in Table 2. The results from
the Epworth sleepiness scale (ESS) demonstrated OSA pa-
tients significantly sleepier when compared to controls
(noOSA p = 0.008 and oOSA p = 0.004, respectively). Also,
the slow wave sleep (N3) was significantly lower for the OSA
groups compared to controls (noOSA: p = 0.008 e oOSA p =
0.019). Sleep fragmentation, defined by the arousal index
(AI), was higher in all SRBD groups compared to controls
(UAR p < 0.001, noOSA p < 0.001 and oOSA p < 0.001, re-
spectively). Between the three SRBD groups, we detected
differences between UAR and OSA groups (noOSA p =
0.002, oOSA p = 0.029).
Hypoxia-related parameters including the apnea/hypopnea
index (AHI), the oxygen desaturation index (ODI) and the
percentage of peripheral oxygen saturation < 90% (T90) were
significantly higher in both OSA groups when compared to
either controls or UAR patients (Table 2). The respiratory
disturbance index (RDI) was higher in all SRBD patients
compared to controls (UAR p < 0.001, noOSA p < 0.001 and
oOSA p < 0.001). Within the SRBD groups the RDI was
found significantly higher in both OSA groups compared to
UAR (noOSA p < 0.001 and controls p < 0.001). Following
CPAP therapy, all polysomnographic parameters improved
significantly (p < 0.05) with exception of sleep efficiency, that
further decreased, R, and SSS. Results are demonstrated in
Table 3 of the online supplementary material.
Routine laboratory analysis
Results for the routine blood analysis are listed in Tables 3 and
4. No significant difference was found in the full blood count
analysis. The gGT level was twofold higher in all SRBD
groups when compared to the control group (Fig. 2).
Interestingly, median values were quite homogeneous be-
tween the three SRBD groups although the significance was
Fig. 1 (A) Plot showing the gated
lymphocytes in CD3-PECY5 on
the x-axis versus γδ-PE on the y-
axis. The graphic demonstrates an
unusual high percentage of γδ T
cells within the total lymphocytes.
(B) Gating and calculating the
percentage of the of perforin
positive CD3+ γδ T lymphocytes
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higher in OSA patients (UAR p = 0.011; noOSA p = 0.001,
oOSA, p < 0.001). ALT was also elevated in the SRBD pa-
tients, but only in oOSA patients statistically significant when
compared to controls (p = 0.026) Serum glucose level was
significantly higher in oOSA patients compared to controls
(p = 0.013). We found no statistical significant differences in
total cholesterol. The same applied for LDL. HDL was only
significantly higher in the UAR group compared to oOSA
(p = 0.004). Interestingly, the triglycerides were significantly
higher in both OSA groups compared to either controls
(noOSA p = 0.042; oOSA p = 0.015) or UAR patients
(noOSA p = 0.013; oOSA p = 0.013). CRP level showed evi-
dences of differences in the oOSA group when compared to
controls (p = 0.021) and UAR patients (p = 0.021).
Lymphocyte subsets
The main results may be observed in table one of the supple-
mentary information. Flow cytometric analysis revealed a
lower percentage of NK cells in controls compared to
Table 2 Polysomnography
results and sleep questionnaires Controls UAR noOSA oOSA
SE [%] 85.30
(79.98–88.70)
81.00
(74.95–88.20)
83.50
(75.65–86.97)
84.40
(78.90–89.20)
N3 [%] 19.65 *#
(14.53–23.85)
14.80
(9.40–21.50)
10.60
(5.03–15.98)
6.90
(3.60–18.70)
R [%] 12.35
(9.30–15.38)
13.30
(10.35–16.05)
11.40
(8.45–15.55)
12.10
(7.30–14.30)
Arousal Index [/h] 18.70 + *#
(14.10–21.00)
30.50^§
(26.50–38.60)
52.25
(41.50–59.77)
52.20
(32.70–72.40)
AHI [/h] 0.45 + *#
(0.00–1.40)
2.10 ^§
(0.90–3.00)
24.50 °
(11.82–34.98)
51.00
30.90–76.60)
RDI [/h] 2.45 + *#
(1.00–4.28)
10.70 ^§
(8.05–15.05)
34.20
(25.93–52.15)
63.40
(36.50–82.60)
Mean SpO2 [%] 96.00 *#
(96.00–97.00)
96.00 ^§
(95.50–96.00)
94.50°
(94.00–95.00)
93.00
(92.00–94.00)
ODI [/h] 0.70 + *# (0.30–1.48) 1.80 ^§
(1.35–3.50)
20.60 °
(12.53–41.65)
42.70
(28.40–69.30)
T 90 [%] 0.00 *#
(0.00–0.00)
0.00 ^§
(0.00–0.00)
1.00 °
(0.30–4.00)
7.10
(2.20–18.10)
LMI [/h] 7.00 *#
(4.65–11.38)
13.40
(7.90–20.70)
22.30
(11.53–34.35)
29.70
(15.00–46.00)
SSS [P] 2.00
(2.00–3.00)
2.00
(1.00–3.00)
3.00
(2.25–3.00)
3.00
(1.75–3.00)
ESS [P] 4.00 *#
(2.00–6.50)
6.00
(2.00–10.00)
9.50
(6.50–14.75)
9.00
5.00–12.00)
All values are demonstrated asmedian (interquartile range). Statistically significant results after adjustment, with a
p < 0.05 are indicated as: Control vs. UAR: +, Control vs. noOSA: *, Control vs. oOSA: #, UAR vs. noOSA: ^.
UAR vs. oOSA: §, noOSA vs. oOSA: °
UAR: Upper Airway Resistance, noOSA: non-obese OSA, oOSA: obese OSA, SE: Sleep efficiency, N3: stage
N3 sleep (slow wave sleep), AHI: apnea/hypopnea index, RDI: respiratory disturbance index, mean SpO2: mean
peripheral saturation of oxygen. T90: percentage of oxygen saturation < 90%, LMI: Leg movement index of the
lower limbs, SSS: Stanford Sleepiness Scale, ESS Epworth Sleepiness Scale
Table 1 Anthropometric data
Controls (n:24) UAR (n:19) noOSA (n:20) oOSA(n:24)
Age total [years] 37.71 ± 8.82 *# 41.42 ± 7.90 47.75 ± 8.42 47.04 ± 10.21
BMI [kg/m2] ± SD 25.33 ± 2.34# 25.44 ± 2.44§ 25.87 ± 2.26° 33.23 ± 2.91
All results are presented by mean (± SD). Statistically significant results after adjustment, with a p < 0.05 are
indicated as: Control vs. UAR: +, Control vs. noOSA: *, Control vs. oOSA: #, UAR vs. noOSA: ^. UAR vs.
oOSA: §, noOSA vs. oOSA: °
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noOSA and in UAR patients compared to the two OSA
groups. However, such results were not statistically
significant.
Measurement of intracellular perforin
and granzyme-B
To study the cytotoxic function, we focused on granzyme B-
positiveγδ-cells and perforin-positive γδ-cells (Fig. 1).While
for granzyme-B cells there were not sufficient evidences
among groups, perforin-positive γδ-cells revealed significant
differences between groups (p = 0.01662, Fig. 3), especially
between the control group and the oOSA (p = 0.04); the re-
maining SRBD groups showed differences from the control
without reaching statistical significance (control vs UAR: p =
0.08; control vs noOSA = 0.09, Fig. 3).
These results are already an indication of an association be-
tween sleep-related breathing disorders and the cytotoxicity of
the immune system; however, to fully test this association, we
performed a correlation analysis between the perforin-positive
γδ-cells and sleep-related parameters. Using the non-parametric
Spearman Correlation Coefficient approach, we found correla-
tions for AHI (Coef = −0.3568; p = 0.001), RDI (Coef =
−0.3030; p= 0.007), Mean SpO2 (Coef = 0.4750; p < 0.001),
T90 (Coef = −0.3880; p < 0.001), ODI (Coef = −0.3395; p =
0.002), SSS (Coef. = −0.2719; p= 0.022) and ESS (Coef. =
−0.2550; p = 0.025).
These results suggest a relationship between sleep
breathing-related disorders and the perforin-positive γδ-cells,
but because there are other parameters that may influence the
cytotoxicity of the immune system—age, BMI, metabolic
function (and others)—we further analyzed the data to check
Table 3 Routine blood analysis
Controls UAR noOSA oOSA
Hb[g/dl] 15.70
(15.00–16.10)
15.10
(14.65–15.68)
15.10
(14.78–15.57)
15.00
(14.05–15.95)
HCT[%] 45.30
(41.60–47.40)
44.20
(42.77–45.27)
44.00
(42.20–46.35)
44.20
(41.30–46.95)
Leucocytes [10^9/L] 7.27
(5.75–8.27)
6.20
(5.48–6.90)
7.22
(5.76–9.88)
6.89
(5.85–8.19)
Lymphocytes [10^9/L] 2.44
(1.97–2.82)
2.25
(2.05–2.55)
2.53
(2.01–2.95)
2.79
(2.13–3.02)
Creatinine [mg/dl] 1.02
(0.89–1.12)
1.00
(0.95–1.14)
0.93
(0.88–1.00)
0.95
(0.88–1.06)
BUN [mg/dl] 18.46
(16.59–21.50)
18.69
(16.94–21.03)
17.76
(14.72–19.63)
18.46
(16.24–22.31)
AST [U/L] 23.00
(19.75–25.25)
23.00
(20.25–25.00)
25.00
(21.00–30.50)
27.50
(22.75–29.75)
ALT [U/L] 26.00 #
(19.00–29.00)
29.50
(24.25–31.75)
36.00
(22.00–52.00)
38.00
(26.25–54.00)
gGT 20.00 + *#
(14.00–27.00)
41.00
(24.75–52.00)
44.00
(29.00–65.00)
40.00
(30.75–64.75)
Glucose [mg/dl] 85.00 #
(74.00–89.00)
82.50 §
(75.50–86.00)
90.00
(78.50–111.00)
98.00
(89.00–104.00)
Colesterol tot [mg/dl] 177.00
(170.50–192.50)
212.50
(197.00–233.80)
218.00
(198.00–244.00)
197.50
(177.80–217.50)
LDL [mg/dl] 114.00
(105.50–121.50)
142.00
(113.50–153.80)
145.00
(115.00–167.00)
123.50
(105.00–143.00)
HDL [mg/dl] 42.00
(38.00–48.50)
47.50 §
(44.00–58.00)
44.00
(37.00–50.00)
40.00
(36.25–44.75)
TG [mg/dl] 101.00 *#
(68.50–120.50)
107.00 ^§
(75.25–124.75)
167.00
(152.00–252.00)
163.00
(125.00–221.20)
CRP [mg/dl] 0.04 #
(0.04–0.13)
0.05 §
(0.04–0.14)
0.12
(0.05–0.51)
0.30
(0.14–0.43)
All values are demonstrated as median (interquartile range). Statistically significant results after adjustment, with a p < 0.05 are indicated as: Control vs.
UAR: +, Control vs. noOSA: *, Control vs. oOSA: #, UAR vs. noOSA: ^. UAR vs. oOSA: §, noOSA vs. oOSA: °
UAR: Upper Airway Resistance, noOSA: non-obese OSA, oOSA: obese OSA, Hb: hemoglobin, HCT: hematocrite, BUN: Blood Ureia Nitrogen, AST:
Apartate Aminotransferase, ALT: Alanine Aminotransferase, gGT:gamma glutamyl transferase, LDL: Low-density lipoprotein Cholesterol, HDL: high-
density lipoprotein cholesterol, TG: Triglycerides, CRP: C-reactive Protein
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whether the identified associations were maintained when
such confounding variables are taken into consideration. To
this end, we performed a multiple regression analysis, a meth-
od that is highly recommended for these situations. The mul-
tiple regression analysis results showed that even when sever-
al parameters were taken into consideration, SRBD-related
variables such as Arousal Index (p = 0.049) and Mean SpO2
(p = 0.050) were still associated with the perforin-positive γδ-
cells. The overall model also demonstrated to be better than a
stochastic model (p = 0.039).
Measurement of intracellular perforin
and granzyme-B following therapy with continuous
positive airway pressure (CPAP)
Following CPAP therapy the percentage of perforin positive
cells within the lymphocyte subgroups increased with excep-
tion of the CD3−CD8+P+/CD3−CD8+ lymphocytes (Table 4
supplementary material). Only for the CD3+CD4+P+/
CD3+CD4+ lymphocytes there was statistically relevant evi-
dences of differences (p = 0.022). We found no statistically
Table 4 Percentage of perforin positive lymphocytes within the lymphocyte subset
Controls UAR OSAS non obese OSAS obese
Total Perforin 23,60
(20.70–37.00)
19.40
(16.10–27.20)
22.60
(17.65–30.02)
24.90
(17.27–32.75)
CD3+P+/CD3+ 12.40
(8.49–20.30)
13.75
(8.29–16.40)
14.65
(7.91–24.03)
15.70
(9.32–23.40)
CD3+CD4+P+/CD3+CD4+ 1.60
(0.64–4.19)
2.28
(0.66–5.35)
1.63
(0.84–3.18)
1.60
(0.29–6.82)
CD3+CD8+P+/CD3+CD8+ 28.50
(15.32–51.62)
28.20
(17.10–49.15)
24.80
(18.20–44.00)
30.55
(20.62–48.48)
CD3−CD8+P+/CD3−CD8+ 66.35
(48.50–85.12)
85.80
(71.70–91.10)
79.75
(67.83–92.03)
84.90
(69.25–95.05)
CD3+γδP+/ CD3+gd 65.10 #
(57.90–79.30)
46.20
(36.45–60.10)
45.95
(29.10–62.90)
38.75
(25.20–66.03)
CTLP+/CTL 90.90
(77.90–95.30)
86.15
(81.80–93.55)
86.70
(68.30–94.80)
86.45
(78.90–94.85)
NKP+/NK 98.20
(94.80–99.10)
96.00
(94.75–98.62)
95.20
(93.00–96.95)
95.75
(92.22–97.55)
All values are demonstrated as median (interquartile range). Statistically significant results after adjustment, with a p < 0.05 are indicated as: Control vs.
UAR: +, Control vs. noOSA: *, Control vs. oOSA: #, UAR vs. noOSA: ^. UAR vs. oOSA: §, noOSA vs. oOSA: °
Gd cells: CD3+ ©™ T cells, CTL: CD3 +CD16 + CD56+ cell. NK: CD3-CD16 + CD56+ positive cells
Fig. 2 γGT levels in controls,
upper airway resistance (UAR),
lean obstructive sleep apnea
(noOSA), and obese OSA
(oOSA) patients. Statistical
significance is indicated by *.
Both OSA groups demonstrate a
relatively similar pattern
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significant impact of the CPAP therapy in the GrB positive
lymphocytes.
In vitro measurement of degranulation capacity
and intracellular perforin and granzyme-B following
hypoxia of human γδ-T cells
To investigate whether intermittent hypoxia seen in sleep ap-
nea patients is causally linked to decreased perforin levels in
γδ-T cells, we isolated γδ-T cells from six independent anon-
ymous donors from a blood bank and tested for their degran-
ulation capacity, as measured by CD107a surface expression,
perforin and granzyme B, comparing normal oxygen levels
and hypoxic conditions. We observed a substantial and statis-
tical significant decrease in the degranulation capacity of γδ-T
cells in hypoxic conditions as evidenced by reduced levels of
CD107a staining (Fig. 4a). We also found decreased levels of
granzyme-B despite not being statistically significant
(similarly to our patients, Fig. 4b), but no change in the
perforin levels (Fig. 4c).
Discussion
Sleep disturbances, including sleep-related breathing disor-
ders (SRBD) in general and the obstructive sleep apnea
(OSA) in particular, are known to contribute human homeo-
stasis disruption [14] but the underlying mechanisms remain
poorly understood. In OSA, the intermittent hypoxia due to
either apneas or hypopneas and the sleep fragmentation due to
the respiratory effort are the most important candidate mech-
anisms so far implicated.
In this study, we found that obstructive respiratory events
including obstructive apnea, obstructive hypopnea, and respi-
ratory effort-related arousals (RERA) are associated with a
reduced percentage of perforin positive CD3+γδ T cells.
Even in upper airway resistance patients (UAR) who by def-
inition do not exhibit relevant oxygen desaturations, we saw
some indications of this reduction, suggesting that sleep frag-
mentation, not only intermittent hypoxia, can influence the
cytotoxic immune system.
Interestingly, therapy of OSAwith continuous positive air-
way pressure (CPAP) increased the percentage of perforin-
positive cells in most lymphocyte subpopulations (the differ-
ences were statistically significant only for CD3+CD4+ lym-
phocytes), suggesting that CPAP treatment is able to revert the
observed decrease in perforin levels.
We have also investigated whether intermittent hypoxia
could be causally linked to the changes observed and suffi-
cient to explain the decrease in perforin levels found in the
CD3+γδ T cells of patients. We did find that there are signif-
icant differences in the degranulation capacity of γδ T cells
subjected to hypoxia as well as decreased levels of granzyme
B, but no changes in the levels of perforin. These findings do
suggest that hypoxia changes the degranulation capacity of
CD3+γδ T cells in patients, but it is not sufficient to change
the perforin level, which might be in direct connection to sleep
fragmentation as suggested by the in vivo findings (UAR
patients, who have no intermittent hypoxia, also have de-
creased perforin levels). The fact that we did not find changes
in the levels of perforin might also reflect experimental
Fig. 3 Perforin-positive CD3+γδ-
T lymphocytes. Statistical
significant results are indicated by
*. All three sleep-disordered
breathing groups demonstrate a
similar distribution with a
significant result in the statistical
analysis for the oOSAwhen
compared with the controls
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limitations as it was not possible to mimic intermittent hypox-
ia and we were limited to continuous hypoxia. In addition,
because we got samples from anonymous donors of a blood
bank, we cannot exclude that some of the samples came from
sleep apnea patients, as we know that the prevalence is very
high in the general population [15]. By the current epidemio-
logical data, it is possible that up to two out of the six samples
came from donors with some level of SRBD. If this was the
case, our in vitro experiment underestimated the real impact of
hypoxia on the degranulation capacity of CD3+γδ T cells.
There have been few studies investigating the influence of
OSA on the cellular immune system. Dyugovskaya and col-
leagues found an increased cytotoxic activity against endothe-
lial cells for both γδ T cells and CD8+ lymphocyte in OSA
patients [16, 17]. Although, at least at first glance, these results
appear contradictory to ours, in fact they are not mutually
exclusive. The described increased cytotoxicity of γδ T cells
in OSA patients was TNF-α dependent and not based on the
perforin/granzyme B pathway which is in general considered
the faster and most effective mechanism of lymphocyte medi-
ated cytotoxicity [6]. In our study, the percentage of perforin-
positive CD8+ lymphocytes not expressing CD3 was higher in
all three SRBD groups. This CD8+ lymphocyte subset is con-
sidered the most cytotoxic cells within all CD8 lymphocytes,
especially when expressing CD56 [18]. Following one night of
CPAP therapy, the percentage of perforin positive CD3−CD8+
lymphocytes decreased although the result was not statistically
significant. Thus, in this small subset we observed the same
trend as Dyugovskaya and colleagues.
It is currently unclear if the cytotoxic defense in OSA is
increased [17], normal [19] or even decreased. Recently,
Gaoatswe and colleagues demonstrated that circulating invari-
ant natural killer T cells (iNKT) are reduced in OSA patients
[20]. The more severe patients revealed the lowest number of
iNKT lymphocytes. Incubation in a hypoxic environment in-
creased apoptosis and decreased cytotoxicity of iNKT lym-
phocytes. Recent research provided evidence that OSA might
increase the risk of cancer (reviewed by Gozal et al. [21]).
Since invariant NKT cells are important for the anti-tumor
response, Gaoatswe and colleagues suggested their results
might contribute to explain the possible relationship between
OSA and cancer. The γδ Tcells are a critical component of the
anti-tumor capabilities of the human immune response [22].
Therefore, our results constitute an important contribution to
mechanistically explain the epidemiological relation between
OSA and tumor diseases. The percentage of γδ T cells in the
peripheral blood is small and usually less than 5%. However,
γδ T cells demonstrate a high migratory capability with rele-
vant accumulation in specific tissues [23, 24]. The decrease of
perforin-positive γδ T cells in the peripheral blood that we
describe might reflect a more important depression of the cy-
totoxic γδ T cells within epithelial tissues [25]. Interestingly,
in a recent study Akparpour and colleagues showed that both
intermittent hypoxia and sleep fragmentation reduces GrB+
CD8 lymphocytes within the tumor environment, in a mouse
model of OSA [26].
Until now the epidemiological data for a possible OSA-
cancer relation foundmainly an association between nocturnal
hypoxemia and cancer mortality [27]. The evidence regarding
non-hypoxic sleep disturbances and tumor diseases is less
established and mostly related to sleep restriction, insomnia,
or shift work investigations with inconsistent results. Perhaps
these conclusions can be explained by the lack of objective
sleep data and abundance of subjective data based on ques-
tionnaires and sleep diaries. In the better-controlled animal
studies both sleep fragmentation and intermittent hypoxia af-
fected various components of the tumor progression including
tumor growth or metastasis [28], which is in excellent agree-
ment with the findings that we now report. The influence of
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Fig. 4 In vitro analysis of degranulation capacity (A), granzyme B, (B)
and perforin (C) CD3+γδ-T lymphocytes, comparing normal levels of
oxygen and hypoxia
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obstructive sleep disordered breathing on tumor diseases was
not the subject of the current study but our data suggests that
both sleep fragmentation and hypoxia influence the cytotoxic
immune defense independently and cumulatively.
Our study protocol did not include special diet recommen-
dations prior to the sleep study, nor did we control for glucose
or cholesterol affecting medication as we did not set out to
investigate if RERAs are capable to influence the metabolic
system. Therefore, the results regarding the glucose, choles-
terol, and lipoprotein analysis should be interpreted cautious-
ly. However, it appears noteworthy to mention that the gGT
was significantly higher in all SRBD groups without any rel-
evant difference between each other. To our knowledge, there
is no evidence regarding the impact of respiratory effort relat-
ed sleep fragmentation on the liver enzymes and this result
deserves further investigation. CRPwas higher in other oOSA
groups when compared to either UAR patients or controls,
confirming previous reports [29]. Also, it is of interest that
controls and upper airway resistance patients had a signifi-
cantly lower triglyceride level when compared to both OSA
groups, although none of them was on regular medication.
With the reservations mentioned, it is possible that apneas
and hypopneas with relevant oxygen desaturation increase,
independently from obesity, the pro-atherogenic role choles-
terol and lipoprotein metabolism [30].
There are some limitations to the interpretation of the sta-
tistical results. The mean age was higher in the OSA groups
when compared to controls. However, UAR patients had no
significantly different age when compared to the other three
investigated groups. In fact, these patients would be consid-
ered controls if less attention had been attributed to the
RERAs classification. Any significant result in UAR patients
compared to controls or OSA patients must be therefore con-
sidered significant. The immunosenescence described for the
percentage of natural killer cells and the perforin related cyto-
toxicity might be of some concern [31]. Nevertheless, most
evidence has been found in patientswith an age above 60 years
[32]. In our study, the inclusion was limited to an age below
60 years with a mean age of 47 years. It is thus questionable if
imunosenescence already has any effect. Also of importance
is the fact that there are only a small number of patients in-
cluded in each group. However, with a total number of 87
included patients the study population is higher than most
other studies investigating the relationship between SRBD
and the immune system. In the future, to fully test the validity
of our conclusions, a study on a more homogeneous group
could be more effective.
In conclusion, this study analyzed the effect of hypoxic and
non-hypoxic respiratory events on the perforin and granzyme-
B positive lymphocytes. We found a decreased percentage of
perforin positive CD3+γδ lymphocytes for the oOSA patients.
Our results suggest that the sleep fragmentation and intermit-
tent hypoxia observed in OSA cause changes in the cytotoxic
potential of CD3+γδ lymphocytes which might be causally
related to the increased cancer risk in these patients.
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